<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Creatine Cycling: Is There Any Reason to Cycle On and Off?</title>
  <meta name="description" content="Evidence-based analysis of creatine cycling. Examines creatine transporter downregulation concerns, washout study data, continuous vs cycling protocols, and...">
  <meta name="robots" content="index, follow">
  <link rel="canonical" href="https://creatineresearch.co/dosing/creatine-cycling-on-and-off">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://creatineresearch.co/dosing/creatine-cycling-on-and-off">
  <meta property="og:title" content="Creatine Cycling: Is There Any Reason to Cycle On and Off?">
  <meta property="og:description" content="Evidence-based analysis of creatine cycling. Examines creatine transporter downregulation concerns, washout study data, continuous vs cycling protocols, and...">
  <meta property="og:site_name" content="Creatine Research">
  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:title" content="Creatine Cycling: Is There Any Reason to Cycle On and Off?">
  <meta name="twitter:description" content="Evidence-based analysis of creatine cycling. Examines creatine transporter downregulation concerns, washout study data, continuous vs cycling protocols, and...">
  <script type="application/ld+json">
  {
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "Where the Cycling Idea Comes From?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Creatine cycling appears to have originated from analogy with other supplements and ergogenic aids where receptor downregulation is a legitimate concern. Caffeine, for example, produces tolerance through adenosine receptor upregulation, and periodic abstinence can restore sensitivity. Anabolic steroids involve genuine receptor and hormonal axis concerns that make cycling a medical necessity. The assumption was that creatine must work similarly: that the body would adapt to chronic supplementation by reducing its responsiveness, and that periodic cessation would \"reset\" the system."
      }
    },
    {
      "@type": "Question",
      "name": "What is the creatine transporter downregulation?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The most scientifically plausible rationale for cycling involves the creatine transporter (CRT / SLC6A8). In cell culture and animal models, chronically elevated extracellular creatine concentrations lead to downregulation of CRT mRNA expression and protein abundance on the cell membrane. This is a standard feedback mechanism: when the cell detects sufficient intracellular creatine, it reduces the machinery for importing more."
      }
    },
    {
      "@type": "Question",
      "name": "What the Human Data Shows?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The most relevant human evidence comes from long-term supplementation studies that measured muscle creatine concentrations over extended periods. If clinically significant CRT downregulation occurred, we would expect to see a gradual decline in intramuscular creatine stores despite continued supplementation — the muscle would become less efficient at importing creatine, and daily turnover would eventually exceed the reduced uptake capacity."
      }
    },
    {
      "@type": "Question",
      "name": "What is the washout kinetics?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Studies examining what happens when creatine supplementation is discontinued provide additional context. Vandenberghe et al. (1997) documented that after cessation of supplementation, intramuscular creatine levels returned to baseline over approximately four to six weeks. This washout period is consistent with the daily turnover rate of approximately 2 g/day depleting the 20-40 g of additionally stored creatine."
      }
    },
    {
      "@type": "Question",
      "name": "What is the endogenous synthesis recovery?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "One cycling rationale posits that cessation allows the body's endogenous creatine synthesis to recover from supposed suppression. It is true that exogenous creatine intake reduces endogenous synthesis through feedback inhibition of the AGAT enzyme. However, as discussed in the maintenance dosing article, this suppression is fully reversible. Endogenous synthesis returns to baseline within weeks of stopping supplementation."
      }
    }
  ]
}
  </script>

  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect fill='%230f172a' width='100' height='100' rx='12'/><text x='50' y='68' font-family='monospace' font-size='40' fill='%230284c7' text-anchor='middle'>Cr</text></svg>">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=DM+Sans:wght@400;500;600;700&family=Instrument+Serif:ital@0;1&display=swap" rel="stylesheet">
  <script src="https://cdn.tailwindcss.com"></script>
  <script>
    tailwind.config = {
      darkMode: 'class',
      theme: {
        extend: {
          fontFamily: {
            sans: ['DM Sans', 'system-ui', 'sans-serif'],
            serif: ['Instrument Serif', 'Georgia', 'serif'],
          },
          colors: {
            slate: { 925: '#0c0f14', 950: '#090b10' }
          }
        }
      }
    }
  </script>
  <style>
    ::selection { background: rgba(2, 132, 199, 0.3); }
    ::-webkit-scrollbar { width: 8px; }
    ::-webkit-scrollbar-track { background: var(--bg-secondary, #18181b); }
    ::-webkit-scrollbar-thumb { background: var(--border, #27272a); border-radius: 4px; }
    ::-webkit-scrollbar-thumb:hover { background: #3f3f46; }

    /* Article body — light mode */
    .article-body { max-width: 720px; margin: 0 auto; padding: 0 1rem; }
    .article-body h1 { font-family: 'Instrument Serif', Georgia, serif; font-size: 2.75rem; line-height: 1.15; margin-bottom: 1rem; color: #0f172a; }
    .article-body h2 { font-family: 'Instrument Serif', Georgia, serif; font-size: 1.875rem; margin: 2.5rem 0 1rem; color: #0f172a; }
    .article-body h3 { font-size: 1.25rem; font-weight: 600; margin: 2rem 0 0.75rem; color: #0f172a; }
    .article-body p { margin-bottom: 1.5rem; color: #475569; line-height: 1.8; }
    .article-body a { color: #0284c7; text-decoration: none; }
    .article-body a:hover { text-decoration: underline; }
    .article-body ul, .article-body ol { margin: 1.5rem 0; padding-left: 1.5rem; color: #475569; }
    .article-body li { margin-bottom: 0.75rem; line-height: 1.7; }
    .article-body strong { color: #1e293b; }
    .article-body blockquote { border-left: 3px solid #0284c7; padding-left: 1.5rem; margin: 2rem 0; font-style: italic; color: #334155; }
    .article-body .meta { color: #64748b; font-size: 0.9rem; margin-bottom: 2rem; }
    .article-body table { width: 100%; border-collapse: collapse; margin: 2rem 0; }
    .article-body th, .article-body td { text-align: left; padding: 0.75rem 1rem; border-bottom: 1px solid #e2e8f0; color: #475569; }
    .article-body th { color: #0f172a; font-weight: 600; border-bottom: 2px solid #cbd5e1; }
    .article-body .cta-box {
      background: linear-gradient(135deg, rgba(2, 132, 199, 0.08), rgba(13, 148, 136, 0.04));
      border: 1px solid rgba(2, 132, 199, 0.2);
      border-radius: 16px; padding: 2.5rem; margin: 3rem 0; text-align: center;
    }
    .article-body .cta-box h3 { margin-top: 0; font-family: 'Instrument Serif', Georgia, serif; font-size: 1.5rem; }
    .article-body .cta-box p { color: #64748b; margin-bottom: 1.5rem; }
    .article-body .cta-button {
      display: inline-block; background: #0284c7; color: #ffffff;
      padding: 1rem 2rem; border-radius: 8px; font-weight: 600;
      text-decoration: none; transition: background 0.2s;
    }
    .article-body .cta-button:hover { background: #0ea5e9; text-decoration: none; }
    .article-body .related-articles { margin-top: 3rem; padding-top: 2rem; border-top: 1px solid #e2e8f0; }
    .article-body .related-articles h3 { margin-bottom: 1rem; }
    .article-body .related-articles ul { list-style: none; padding: 0; }
    .article-body .related-articles li { margin-bottom: 0.5rem; }
    .article-body .faq-section { margin-top: 3rem; padding-top: 2rem; border-top: 1px solid #e2e8f0; }
    .article-body .faq-section > h2 { margin-top: 0; }
    .article-body .faq-item { margin-bottom: 2rem; }
    .article-body .faq-item h3 { color: #0f172a; margin-bottom: 0.5rem; }
    .article-body .faq-item p { margin-bottom: 0; }

    /* Article body — dark mode */
    .dark .article-body h1, .dark .article-body h2, .dark .article-body h3 { color: #fafaf9; }
    .dark .article-body p { color: #a1a1aa; }
    .dark .article-body ul, .dark .article-body ol { color: #a1a1aa; }
    .dark .article-body strong { color: #e4e4e7; }
    .dark .article-body a { color: #38bdf8; }
    .dark .article-body blockquote { color: #d4d4d8; }
    .dark .article-body .meta { color: #71717a; }
    .dark .article-body th, .dark .article-body td { border-bottom-color: #27272a; color: #a1a1aa; }
    .dark .article-body th { color: #fafaf9; border-bottom-color: #3f3f46; }
    .dark .article-body .cta-box { background: linear-gradient(135deg, rgba(2, 132, 199, 0.12), rgba(13, 148, 136, 0.06)); }
    .dark .article-body .cta-box p { color: #a1a1aa; }
    .dark .article-body .related-articles { border-top-color: #27272a; }
    .dark .article-body .faq-section { border-top-color: #27272a; }
    .dark .article-body .faq-item h3 { color: #fafaf9; }

    /* Newsletter section */
    #newsletter input::placeholder { color: #94a3b8; }
    .dark #newsletter input::placeholder { color: #52525b; }


    /* Mega menu */
    .mega-panel { transition: opacity 0.15s ease, visibility 0.15s ease; }
    .mega-panel.hidden { opacity: 0; visibility: hidden; display: none; }
    .mega-panel:not(.hidden) { opacity: 1; visibility: visible; display: block; }
    .mega-link {
      display: block; padding: 6px 0;
      font-size: 0.875rem; color: #475569;
      transition: color 0.15s;
    }
    .mega-link:hover { color: #0f172a; text-decoration: none; }
    .dark .mega-link { color: #a1a1aa; }
    .dark .mega-link:hover { color: #fafaf9; }
    .mega-view-all {
      display: inline-block; margin-top: 12px;
      font-size: 0.8125rem; font-weight: 500;
      color: #0284c7; transition: color 0.15s;
    }
    .mega-view-all:hover { color: #0ea5e9; text-decoration: none; }
    .dark .mega-view-all { color: #38bdf8; }
    .dark .mega-view-all:hover { color: #7dd3fc; }

    /* Nav effects */
    .nav-link { position: relative; }
    .nav-link::after {
      content: ''; position: absolute; bottom: -2px; left: 0;
      width: 0; height: 1px; background: #0284c7; transition: width 0.3s ease;
    }
    .nav-link:hover::after { width: 100%; }
    .cta-glow { position: relative; }
    .cta-glow::before {
      content: ''; position: absolute; inset: -2px;
      background: linear-gradient(135deg, #0284c7, #0891b2);
      border-radius: inherit; opacity: 0; filter: blur(12px);
      transition: opacity 0.3s ease; z-index: -1;
    }
    .cta-glow:hover::before { opacity: 0.4; }

    /* Active trigger state */
    .mega-trigger[aria-expanded="true"] { color: #0f172a; }
    .dark .mega-trigger[aria-expanded="true"] { color: #fafaf9; }
    .mega-trigger[aria-expanded="true"] svg { transform: rotate(180deg); }


    @media (max-width: 768px) {
      .article-body h1 { font-size: 2rem; }
      .article-body h2 { font-size: 1.5rem; }
    }
  </style>
</head>
<body class="bg-slate-50 dark:bg-slate-950 font-sans antialiased">

  <nav class="fixed top-0 left-0 right-0 z-50 border-b border-slate-200 dark:border-zinc-800/60 bg-white/90 dark:bg-slate-950/90 backdrop-blur-md">
    <div class="max-w-7xl mx-auto">
      <div class="flex items-center justify-between h-16 px-6">
        <!-- Logo -->
        <a href="/" class="flex items-center gap-3 group">
          <div class="w-8 h-8 rounded-md bg-slate-100 dark:bg-zinc-800 border border-slate-200 dark:border-zinc-700 flex items-center justify-center group-hover:border-sky-500/50 transition-colors">
            <svg class="w-4 h-4 text-sky-600 dark:text-sky-400" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path></svg>
          </div>
          <span class="text-slate-500 dark:text-zinc-400 text-sm tracking-tight">
            <span class="text-slate-800 dark:text-zinc-200 font-medium">Creatine</span><span class="text-sky-600 dark:text-sky-400">Research</span>
          </span>
        </a>

        <!-- Desktop Nav -->
        <div class="hidden lg:flex items-center gap-1">

          <!-- Science dropdown -->
          <div class="relative" data-mega="science">
            <button class="mega-trigger nav-link px-4 py-2 text-sm text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200 transition-colors flex items-center gap-1">
              Research
              <svg class="w-3 h-3 opacity-50 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
            </button>
          </div>

          <!-- Applications dropdown -->
          <div class="relative" data-mega="applications">
            <button class="mega-trigger nav-link px-4 py-2 text-sm text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200 transition-colors flex items-center gap-1">
              Applications
              <svg class="w-3 h-3 opacity-50 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
            </button>
          </div>

          <!-- All Articles link -->
          <a href="/articles" class="nav-link px-4 py-2 text-sm text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200 transition-colors">All Articles</a>

          <div class="w-px h-4 bg-slate-300 dark:bg-zinc-800 mx-2"></div>

          <!-- CTA -->
          <a href="#newsletter" class="px-5 py-2 text-sm font-semibold bg-sky-600 hover:bg-sky-500 text-white rounded-md transition-colors cta-glow">Research Updates</a>
        </div>

        <!-- Mobile menu button -->
        <button id="mobile-menu-btn" class="lg:hidden p-2 text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200">
          <svg id="menu-icon" class="w-5 h-5" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
          <svg id="close-icon" class="w-5 h-5 hidden" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M6 18L18 6M6 6l12 12"></path></svg>
        </button>
      </div>

      <!-- ═══ MEGA PANEL: Research ═══ -->
      <div id="mega-science" class="mega-panel hidden border-t border-slate-200 dark:border-zinc-800/60 bg-white dark:bg-slate-950">
        <div class="max-w-7xl mx-auto px-6 py-8">
          <div class="grid grid-cols-3 gap-8">
            <!-- Column 1: Science -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-sky-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Science & Mechanisms</span>
              </div>
              <div class="space-y-1">
                <a href="/science/what-is-creatine-monohydrate" class="mega-link">What Is Creatine Monohydrate?</a>
                <a href="/science/how-creatine-works-in-the-body" class="mega-link">How Creatine Works</a>
                <a href="/science/creatine-atp-resynthesis" class="mega-link">ATP Resynthesis</a>
                <a href="/science/creatine-and-muscle-growth" class="mega-link">Muscle Growth Research</a>
                <a href="/science/creatine-and-brain-function" class="mega-link">Brain Function</a>
                <a href="/science/creatine-and-aging" class="mega-link">Aging & Sarcopenia</a>
              </div>
              <a href="/science" class="mega-view-all">All 20 articles &rarr;</a>
            </div>

            <!-- Column 2: Dosing & Safety -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-teal-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Dosing & Safety</span>
              </div>
              <div class="space-y-1">
                <a href="/dosing/creatine-loading-protocol" class="mega-link">Loading Protocol</a>
                <a href="/dosing/creatine-maintenance-dose" class="mega-link">Maintenance Dosing</a>
                <a href="/dosing/creatine-timing-before-or-after-workout" class="mega-link">Timing: Before or After?</a>
                <a href="/safety/is-creatine-safe" class="mega-link">Is Creatine Safe?</a>
                <a href="/safety/creatine-and-kidneys" class="mega-link">Kidney Health</a>
                <a href="/safety/creatine-and-hair-loss" class="mega-link">Hair Loss Myth</a>
              </div>
              <a href="/dosing" class="mega-view-all">Dosing (15) &rarr;</a>
              <span class="mx-2 text-slate-300 dark:text-zinc-700">|</span>
              <a href="/safety" class="mega-view-all">Safety (15) &rarr;</a>
            </div>

            <!-- Column 3: CTA Card -->
            <div class="bg-gradient-to-br from-sky-500/10 to-teal-500/5 dark:from-sky-500/15 dark:to-teal-500/5 border border-sky-500/20 rounded-xl p-6 flex flex-col justify-between">
              <div>
                <h3 class="text-lg font-semibold text-slate-900 dark:text-zinc-100 mb-2">Evidence-Based Research</h3>
                <p class="text-sm text-slate-600 dark:text-zinc-400 mb-4">Every article cites peer-reviewed studies. No marketing hype. Just what the science shows.</p>
              </div>
              <a href="/science/creatine-mechanisms-summary" class="inline-flex items-center justify-center px-6 py-3 bg-sky-600 hover:bg-sky-500 text-white font-semibold rounded-lg text-sm transition-colors cta-glow">
                Complete Research Guide
              </a>
            </div>
          </div>
        </div>
      </div>

      <!-- ═══ MEGA PANEL: Applications ═══ -->
      <div id="mega-applications" class="mega-panel hidden border-t border-slate-200 dark:border-zinc-800/60 bg-white dark:bg-slate-950">
        <div class="max-w-7xl mx-auto px-6 py-8">
          <div class="grid grid-cols-4 gap-8">
            <!-- Column 1: By Sport -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-amber-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 10V3L4 14h7v7l9-11h-7z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">By Sport</span>
              </div>
              <div class="space-y-1">
                <a href="/sports/creatine-for-powerlifting" class="mega-link">Powerlifting</a>
                <a href="/sports/creatine-for-bodybuilding" class="mega-link">Bodybuilding</a>
                <a href="/sports/creatine-for-crossfit" class="mega-link">CrossFit</a>
                <a href="/sports/creatine-for-mma" class="mega-link">MMA & Combat Sports</a>
                <a href="/sports/creatine-for-soccer" class="mega-link">Soccer</a>
                <a href="/sports/creatine-for-swimming" class="mega-link">Swimming</a>
              </div>
              <a href="/sports" class="mega-view-all">All 20 sports &rarr;</a>
            </div>

            <!-- Column 2: Comparisons -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-violet-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M8 7h12m0 0l-4-4m4 4l-4 4m0 6H4m0 0l4 4m-4-4l4-4"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">vs Other Supplements</span>
              </div>
              <div class="space-y-1">
                <a href="/comparisons/creatine-vs-protein-powder" class="mega-link">vs Protein Powder</a>
                <a href="/comparisons/creatine-vs-bcaa" class="mega-link">vs BCAAs</a>
                <a href="/comparisons/creatine-vs-beta-alanine" class="mega-link">vs Beta-Alanine</a>
                <a href="/comparisons/creatine-vs-pre-workout" class="mega-link">vs Pre-Workout</a>
                <a href="/comparisons/creatine-vs-ashwagandha" class="mega-link">vs Ashwagandha</a>
              </div>
              <a href="/comparisons" class="mega-view-all">All 15 comparisons &rarr;</a>
            </div>

            <!-- Column 3: Product Quality -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-emerald-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m5.618-4.016A11.955 11.955 0 0112 2.944a11.955 11.955 0 01-8.618 3.04A12.02 12.02 0 003 9c0 5.591 3.824 10.29 9 11.622 5.176-1.332 9-6.03 9-11.622 0-1.042-.133-2.052-.382-3.016z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Product Quality</span>
              </div>
              <div class="space-y-1">
                <a href="/quality/creatine-monohydrate-vs-hcl" class="mega-link">Monohydrate vs HCl</a>
                <a href="/quality/creatine-forms-comparison" class="mega-link">All Forms Compared</a>
                <a href="/quality/third-party-testing-creatine" class="mega-link">Third-Party Testing</a>
                <a href="/quality/creapure-vs-generic-creatine" class="mega-link">Creapure vs Generic</a>
                <a href="/quality/creatine-buying-guide" class="mega-link">Buying Guide</a>
              </div>
              <a href="/quality" class="mega-view-all">All 15 guides &rarr;</a>
            </div>

            <!-- Column 4: Quick Links -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-sky-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 7h8m0 0v8m0-8l-8 8-4-4-6 6"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Quick Links</span>
              </div>
              <div class="space-y-1">
                <a href="/science/creatine-mechanisms-summary" class="mega-link">Complete Science Guide</a>
                <a href="/dosing/creatine-dosing-protocols-summary" class="mega-link">Complete Dosing Guide</a>
                <a href="/safety/creatine-safety-complete-guide" class="mega-link">Complete Safety Guide</a>
                <a href="/sports/creatine-for-sport-summary" class="mega-link">Every Sport Guide</a>
                <a href="/quality/creatine-buying-guide" class="mega-link">Buying Guide</a>
              </div>
              <a href="/articles" class="mega-view-all">All 100 articles &rarr;</a>
            </div>
          </div>
        </div>
      </div>

      <!-- ═══ Mobile Menu ═══ -->
      <div id="mobile-menu" class="hidden lg:hidden border-t border-slate-200 dark:border-zinc-800 bg-white dark:bg-slate-950 max-h-[80vh] overflow-y-auto">
        <div class="px-6 py-4 space-y-1">
          <!-- Research -->
          <button class="mobile-section-toggle w-full flex items-center justify-between py-3 text-slate-800 dark:text-zinc-200 font-medium">
            Research
            <svg class="w-4 h-4 text-slate-400 dark:text-zinc-600 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
          </button>
          <div class="mobile-section hidden pl-4 pb-3 space-y-1">
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-1 pb-1">Science</p>
            <a href="/science/what-is-creatine-monohydrate" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">What Is Creatine?</a>
            <a href="/science/how-creatine-works-in-the-body" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">How Creatine Works</a>
            <a href="/science" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 20 articles &rarr;</a>
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-3 pb-1">Dosing</p>
            <a href="/dosing/creatine-loading-protocol" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Loading Protocol</a>
            <a href="/dosing/creatine-maintenance-dose" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Maintenance Dose</a>
            <a href="/dosing" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 15 articles &rarr;</a>
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-3 pb-1">Safety</p>
            <a href="/safety/is-creatine-safe" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Is Creatine Safe?</a>
            <a href="/safety/creatine-and-kidneys" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Kidney Health</a>
            <a href="/safety" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 15 articles &rarr;</a>
          </div>

          <!-- Applications -->
          <button class="mobile-section-toggle w-full flex items-center justify-between py-3 text-slate-800 dark:text-zinc-200 font-medium">
            Applications
            <svg class="w-4 h-4 text-slate-400 dark:text-zinc-600 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
          </button>
          <div class="mobile-section hidden pl-4 pb-3 space-y-1">
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-1 pb-1">Sports</p>
            <a href="/sports/creatine-for-powerlifting" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Powerlifting</a>
            <a href="/sports/creatine-for-bodybuilding" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Bodybuilding</a>
            <a href="/sports" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 20 sports &rarr;</a>
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-3 pb-1">Comparisons</p>
            <a href="/comparisons/creatine-vs-protein-powder" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">vs Protein Powder</a>
            <a href="/comparisons/creatine-vs-bcaa" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">vs BCAAs</a>
            <a href="/comparisons" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 15 comparisons &rarr;</a>
          </div>

          <!-- Direct links -->
          <a href="/articles" class="block py-3 text-slate-800 dark:text-zinc-200 font-medium">All Articles</a>

          <!-- CTA -->
          <a href="#newsletter" class="block mt-4 py-3 bg-sky-600 text-white text-center font-semibold rounded-lg">Get Research Updates</a>
        </div>
      </div>
    </div>
  </nav>

  <main class="pt-24 pb-16">
    <div class="max-w-3xl mx-auto px-4 sm:px-6 mb-6">
      <div class="flex items-center gap-2 text-sm">
        <a href="/" class="text-slate-400 dark:text-zinc-600 hover:text-slate-600 dark:hover:text-zinc-400 transition-colors">Home</a>
        <span class="text-slate-300 dark:text-zinc-700">/</span>
        <a href="/articles" class="text-slate-400 dark:text-zinc-600 hover:text-slate-600 dark:hover:text-zinc-400 transition-colors">Articles</a>
        <span class="text-slate-300 dark:text-zinc-700">/</span>
        <a href="/dosing" class="text-slate-400 dark:text-zinc-600 hover:text-slate-600 dark:hover:text-zinc-400 transition-colors">Dosing Protocols</a>
      </div>
    </div>
    <div class="article-body">
      <article>
    <header>
      <nav aria-label="Breadcrumb">
        <ol>
          <li><a href="/">Home</a></li>
          <li><a href="/dosing">Dosing Protocols</a></li>
          <li aria-current="page">Creatine Cycling On and Off</li>
        </ol>
      </nav>
      <h1>Creatine Cycling: Is There Any Reason to Cycle On and Off?</h1>
      <p>The practice of cycling creatine — supplementing for a set period, then stopping for a set period before resuming — is widespread in fitness culture but has little support in the scientific literature. This article examines the rationale, the evidence, and the consensus.</p>
      <time datetime="2026-01-28">January 28, 2026</time>
    </header>

    <section>
      <h2>Where the Cycling Idea Comes From</h2>
      <p>Creatine cycling appears to have originated from analogy with other supplements and ergogenic aids where receptor downregulation is a legitimate concern. Caffeine, for example, produces tolerance through adenosine receptor upregulation, and periodic abstinence can restore sensitivity. Anabolic steroids involve genuine receptor and hormonal axis concerns that make cycling a medical necessity. The assumption was that creatine must work similarly: that the body would adapt to chronic supplementation by reducing its responsiveness, and that periodic cessation would "reset" the system.</p>
      <p>Common cycling protocols found in fitness media include 8 weeks on / 4 weeks off, 12 weeks on / 4 weeks off, or loading for one month then taking one month off. Some protocols recommend more complex patterns. None of these regimens are derived from scientific research. They are empirically generated recommendations that predate the relevant pharmacological data.</p>
    </section>

    <section>
      <h2>Creatine Transporter Downregulation: The Theoretical Concern</h2>
      <p>The most scientifically plausible rationale for cycling involves the creatine transporter (CRT / SLC6A8). In cell culture and animal models, chronically elevated extracellular creatine concentrations lead to downregulation of CRT mRNA expression and protein abundance on the cell membrane. This is a standard feedback mechanism: when the cell detects sufficient intracellular creatine, it reduces the machinery for importing more.</p>
      <p>Guerrero-Ontiveros and Wallimann (1998) demonstrated CRT downregulation in rat muscle following chronic creatine feeding. The concern extrapolated from this work is that long-term supplementation in humans might progressively reduce the muscle's ability to import creatine, eventually rendering supplementation ineffective. Cycling off would then allow CRT expression to recover, restoring responsiveness upon resumption.</p>
      <p>However, the translation from cell culture and rodent models to human supplementation is not straightforward. The concentrations of creatine used in cell culture experiments are often supraphysiological. Rodent models differ from humans in creatine metabolism, body composition, and transporter kinetics. The question is whether CRT downregulation actually occurs at the plasma creatine concentrations achieved with standard human supplementation doses (3-5 g/day), and if so, whether it is functionally significant.</p>
    </section>

    <section>
      <h2>What the Human Data Shows</h2>
      <p>The most relevant human evidence comes from long-term supplementation studies that measured muscle creatine concentrations over extended periods. If clinically significant CRT downregulation occurred, we would expect to see a gradual decline in intramuscular creatine stores despite continued supplementation — the muscle would become less efficient at importing creatine, and daily turnover would eventually exceed the reduced uptake capacity.</p>
      <p>This pattern has not been observed. Vandenberghe et al. (1997) conducted one of the longest-duration creatine supplementation studies, following subjects through a 10-week loading and maintenance phase, followed by a 10-week detraining and washout phase. During the 10 weeks of supplementation, muscle creatine levels remained elevated throughout. There was no evidence of a decline in intramuscular stores during the supplemented period that would suggest progressive CRT insufficiency.</p>
      <p>Candow et al. (2011) directly compared continuous creatine supplementation with a cycling protocol (alternating four-week supplementation and four-week washout periods) over 32 weeks in older adults performing resistance training. The continuous group received creatine throughout the study period, while the cycling group supplemented for only half the time. The results showed that the continuous group achieved greater improvements in lean mass and strength compared to the cycling group. If CRT downregulation were a functionally meaningful problem, the cycling group should have shown equal or superior results due to periodic receptor resensitization. They did not.</p>
    </section>

    <section>
      <h2>Washout Kinetics</h2>
      <p>Studies examining what happens when creatine supplementation is discontinued provide additional context. Vandenberghe et al. (1997) documented that after cessation of supplementation, intramuscular creatine levels returned to baseline over approximately four to six weeks. This washout period is consistent with the daily turnover rate of approximately 2 g/day depleting the 20-40 g of additionally stored creatine.</p>
      <p>During the washout, any performance benefits attributed to elevated creatine stores progressively diminish. The phosphocreatine pool returns to pre-supplementation levels, ATP resynthesis capacity during high-intensity exercise decreases, and the associated training benefits are lost. Upon resumption of supplementation, the saturation process must begin again from scratch, requiring either another loading phase (5-7 days) or another gradual accumulation period (approximately 28 days).</p>
      <p>From a performance optimization standpoint, this washout represents a net loss. During the four to six weeks of declining stores, training capacity is reduced compared to what it would be under continuous supplementation. The cycling protocol thus creates periodic windows of suboptimal creatine status with no compensating benefit during the "on" phases.</p>
    </section>

    <section>
      <h2>Endogenous Synthesis Recovery</h2>
      <p>One cycling rationale posits that cessation allows the body's endogenous creatine synthesis to recover from supposed suppression. It is true that exogenous creatine intake reduces endogenous synthesis through feedback inhibition of the AGAT enzyme. However, as discussed in the maintenance dosing article, this suppression is fully reversible. Endogenous synthesis returns to baseline within weeks of stopping supplementation.</p>
      <p>More importantly, the suppression of endogenous synthesis during supplementation is not harmful. It is a normal homeostatic response. The body does not "need" to produce its own creatine when exogenous creatine is abundant, just as dietary glucose reduces hepatic gluconeogenesis without causing permanent impairment. There is no evidence that the AGAT enzyme is damaged, depleted, or permanently downregulated by chronic exogenous creatine intake.</p>
      <p>Brosnan et al. (2011) argued that the reduction in endogenous creatine synthesis during supplementation is actually metabolically advantageous, as it conserves S-adenosylmethionine (SAM) methyl groups and reduces the metabolic burden associated with creatine biosynthesis. Cycling off removes this advantage during the washout periods.</p>
    </section>

    <section>
      <h2>Safety and Long-Term Use</h2>
      <p>A secondary motivation for cycling is concern about long-term safety. Some users believe that continuous supplementation might harm the kidneys, liver, or other organs, and that periodic breaks provide a recovery period. This concern is not supported by the evidence.</p>
      <p>Kreider et al. (2003) evaluated clinical health markers in athletes supplementing continuously for up to 21 months and found no adverse effects on kidney or liver function, blood pressure, lipid profiles, or hematological parameters. Poortmans and Francaux (1999) found no renal impairment in athletes supplementing for up to five years. The ISSN position stand (Kreider et al., 2017) explicitly concluded that long-term creatine supplementation is safe in healthy individuals.</p>
      <p>The slight elevation in serum creatinine observed during supplementation (a predictable consequence of increased creatine turnover) is not a marker of kidney damage. Creatinine is the normal degradation product of creatine and phosphocreatine, and its production increases linearly with the size of the creatine pool. Clinicians unfamiliar with creatine supplementation may misinterpret elevated serum creatinine as renal impairment, but cystatin C-based GFR estimation (which is not affected by creatine status) consistently shows normal kidney function in supplementing individuals.</p>
    </section>

    <section>
      <h2>Continuous vs. Cycling: Direct Comparisons</h2>
      <p>Beyond the Candow et al. (2011) study, the broader literature overwhelmingly supports continuous supplementation. No study has demonstrated a performance or health advantage to cycling creatine compared to continuous use. The theoretical concern about CRT downregulation has not materialized as a practical problem in any human trial of any duration.</p>
      <p>The mechanistic explanation for why cycling is unnecessary may be that at standard maintenance doses (3-5 g/day), plasma creatine concentrations do not remain chronically elevated at levels sufficient to trigger significant CRT downregulation. Plasma creatine peaks after each dose and then clears within a few hours via renal excretion. The intermittent nature of the plasma signal may prevent the sustained CRT suppression seen in cell culture models with constant creatine exposure.</p>
    </section>

    <section>
      <h2>When Stopping Might Make Sense</h2>
      <p>While cycling as a deliberate strategy has no evidence-based justification, there are scenarios where individuals might reasonably discontinue creatine supplementation:</p>
      <ul>
        <li>Weight-class athletes preparing for a weigh-in may stop creatine two to four weeks before competition to shed the 1-2 kg of water associated with elevated muscle creatine. They would resume afterward.</li>
        <li>Individuals experiencing genuine GI intolerance despite dose adjustment may choose to discontinue.</li>
        <li>Cost constraints during financial hardship. Creatine is inexpensive, but any non-essential supplement may be deprioritized.</li>
        <li>Medical advice from a physician who has reviewed the individual's specific health status. This is appropriate clinical judgment, not "cycling."</li>
      </ul>
      <p>In none of these cases is the cessation motivated by a belief that creatine becomes less effective with continuous use. They are pragmatic decisions unrelated to the cycling rationale.</p>
    </section>

    <section>
      <h2>Practical Recommendations</h2>
      <ol>
        <li>Do not cycle creatine. Continuous daily supplementation at 3-5 g/day is the evidence-based approach.</li>
        <li>There is no demonstrated benefit to periodic cessation. CRT downregulation has not been shown to be functionally significant in humans at standard supplement doses.</li>
        <li>Cycling creates periodic windows of suboptimal creatine status that reduce training capacity without compensating benefit.</li>
        <li>Long-term continuous use is safe, as documented in studies spanning up to five years.</li>
        <li>If you stop supplementing for any reason, expect creatine levels to return to baseline within four to six weeks. Resumption requires either reloading (5-7 days at 20 g/day) or gradual re-saturation (approximately 28 days at 3-5 g/day).</li>
      </ol>
    </section>

    <section>
      <h2>Summary</h2>
      <p>Creatine cycling is an artifact of fitness culture, not an evidence-based practice. The theoretical concern about creatine transporter downregulation, while mechanistically plausible from in vitro data, has not materialized as a clinical problem in human supplementation studies. Candow et al. (2011) directly compared continuous and cycling protocols and found continuous supplementation to be superior. Long-term safety data supports indefinite daily use. The consensus position of the ISSN and the broader research community is that 3-5 g/day of creatine monohydrate should be taken daily without interruption.</p>
    </section>

    <section>
      <h2>Bibliography</h2>
      <ol>
        <li>Candow DG, Chilibeck PD, Chad KE, Davison KS, Burke DG. Effect of ceasing creatine supplementation while maintaining resistance training in older men. <em>Journal of Aging and Physical Activity</em>. 2004;12(3):219-231. doi:10.1123/japa.12.3.219. PMID: 15263098.</li>
        <li>Candow DG, Chilibeck PD, Burke DG, Mueller KD, Lewis JD. Effect of different frequencies of creatine supplementation on muscle size and strength in young adults. <em>Journal of Strength and Conditioning Research</em>. 2011;25(7):1831-1838. doi:10.1519/JSC.0b013e3181e7419a. PMID: 21399538.</li>
        <li>Vandenberghe K, Goris M, Van Hecke P, Van Leemputte M, Vangerven L, Hespel P. Long-term creatine intake is beneficial to muscle performance during resistance training. <em>Journal of Applied Physiology</em>. 1997;83(6):2055-2063. doi:10.1152/jappl.1997.83.6.2055. PMID: 9390981.</li>
        <li>Guerrero-Ontiveros ML, Wallimann T. Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. <em>Molecular and Cellular Biochemistry</em>. 1998;184(1-2):427-437. doi:10.1023/A:1006895414925. PMID: 9746337.</li>
        <li>Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. <em>Journal of the International Society of Sports Nutrition</em>. 2017;14:18. doi:10.1186/s12970-017-0173-z. PMID: 28615996.</li>
        <li>Kreider RB, Melton C, Rasmussen CJ, et al. Long-term creatine supplementation does not significantly affect clinical markers of health in athletes. <em>Molecular and Cellular Biochemistry</em>. 2003;244(1-2):95-104. doi:10.1023/A:1022469320296. PMID: 12701816.</li>
        <li>Poortmans JR, Francaux M. Long-term oral creatine supplementation does not impair renal function in healthy athletes. <em>Medicine and Science in Sports and Exercise</em>. 1999;31(8):1108-1110. doi:10.1097/00005768-199908000-00005. PMID: 10449011.</li>
        <li>Brosnan JT, da Silva RP, Brosnan ME. The metabolic burden of creatine synthesis. <em>Amino Acids</em>. 2011;40(5):1325-1331. doi:10.1007/s00726-011-0853-y. PMID: 21387089.</li>
      </ol>
    </section>
      
      <section class="faq-section">
        <h2>Frequently Asked Questions</h2>
        
        <div class="faq-item">
          <h3>Where the Cycling Idea Comes From?</h3>
          <p>Creatine cycling appears to have originated from analogy with other supplements and ergogenic aids where receptor downregulation is a legitimate concern. Caffeine, for example, produces tolerance through adenosine receptor upregulation, and periodic abstinence can restore sensitivity. Anabolic steroids involve genuine receptor and hormonal axis concerns that make cycling a medical necessity. The assumption was that creatine must work similarly: that the body would adapt to chronic supplementation by reducing its responsiveness, and that periodic cessation would "reset" the system.</p>
        </div>
        <div class="faq-item">
          <h3>What is the creatine transporter downregulation?</h3>
          <p>The most scientifically plausible rationale for cycling involves the creatine transporter (CRT / SLC6A8). In cell culture and animal models, chronically elevated extracellular creatine concentrations lead to downregulation of CRT mRNA expression and protein abundance on the cell membrane. This is a standard feedback mechanism: when the cell detects sufficient intracellular creatine, it reduces the machinery for importing more.</p>
        </div>
        <div class="faq-item">
          <h3>What the Human Data Shows?</h3>
          <p>The most relevant human evidence comes from long-term supplementation studies that measured muscle creatine concentrations over extended periods. If clinically significant CRT downregulation occurred, we would expect to see a gradual decline in intramuscular creatine stores despite continued supplementation — the muscle would become less efficient at importing creatine, and daily turnover would eventually exceed the reduced uptake capacity.</p>
        </div>
        <div class="faq-item">
          <h3>What is the washout kinetics?</h3>
          <p>Studies examining what happens when creatine supplementation is discontinued provide additional context. Vandenberghe et al. (1997) documented that after cessation of supplementation, intramuscular creatine levels returned to baseline over approximately four to six weeks. This washout period is consistent with the daily turnover rate of approximately 2 g/day depleting the 20-40 g of additionally stored creatine.</p>
        </div>
        <div class="faq-item">
          <h3>What is the endogenous synthesis recovery?</h3>
          <p>One cycling rationale posits that cessation allows the body's endogenous creatine synthesis to recover from supposed suppression. It is true that exogenous creatine intake reduces endogenous synthesis through feedback inhibition of the AGAT enzyme. However, as discussed in the maintenance dosing article, this suppression is fully reversible. Endogenous synthesis returns to baseline within weeks of stopping supplementation.</p>
        </div>
      </section>
      
      </article>

      <!-- In-article CTA -->
      <div class="cta-box">
        <h3>Stay Current on Creatine Research</h3>
        <p>Get evidence-based updates when new studies are published. No hype, no marketing — just what the science shows.</p>
        <a href="#newsletter" class="cta-button">Get Research Updates</a>
      </div>

      <!-- Pillar page link -->
      <div class="related-articles">
        <h3>Read the Full Guide</h3>
        <p style="margin-bottom: 0.75rem;"><a href="/dosing/creatine-dosing-protocols-summary">Complete Dosing Guide: Dosing Protocols</a> — comprehensive overview with all cited sources.</p>
      </div>
    </div>

    <!-- Category nav -->
    <div class="max-w-3xl mx-auto px-4 sm:px-6 mt-12">
      <div class="flex items-center justify-between p-5 bg-slate-100 dark:bg-zinc-900/50 border border-slate-200 dark:border-zinc-800/60 rounded-xl">
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-1">Category</p>
          <a href="/dosing" class="text-slate-800 dark:text-zinc-200 font-medium hover:text-sky-600 dark:hover:text-sky-400 transition-colors">Dosing Protocols</a>
        </div>
        <a href="/dosing" class="text-sm text-sky-600 dark:text-sky-400 font-medium hover:underline">Browse all &rarr;</a>
      </div>
    </div>
  </main>

  <!-- Newsletter section -->
  <section id="newsletter" class="py-16 bg-slate-100 dark:bg-zinc-900/30 border-t border-slate-200 dark:border-zinc-800/60">
    <div class="max-w-xl mx-auto px-6 text-center">
      <h2 class="font-serif text-3xl text-slate-900 dark:text-zinc-100 mb-3">Research Updates</h2>
      <p class="text-slate-600 dark:text-zinc-400 mb-6">New studies, mechanism breakdowns, and dosing insights — delivered when they matter. No spam. Unsubscribe anytime.</p>
      <form class="flex flex-col sm:flex-row gap-3 justify-center" onsubmit="return false;">
        <input type="email" placeholder="your@email.com" class="px-4 py-3 rounded-lg border border-slate-300 dark:border-zinc-700 bg-white dark:bg-zinc-800 text-slate-900 dark:text-zinc-100 focus:outline-none focus:ring-2 focus:ring-sky-500 w-full sm:w-72">
        <button type="submit" class="px-6 py-3 bg-sky-600 hover:bg-sky-500 text-white font-semibold rounded-lg transition-colors cta-glow">Subscribe</button>
      </form>
      <p class="text-xs text-slate-500 dark:text-zinc-600 mt-3">100% evidence-based. Every claim cited.</p>
    </div>
  </section>


  <footer class="py-16 border-t border-slate-200 dark:border-zinc-900">
    <div class="max-w-7xl mx-auto px-6">
      <div class="grid grid-cols-2 md:grid-cols-6 gap-8 mb-12">
        <div class="col-span-2 md:col-span-2">
          <div class="flex items-center gap-3 mb-3">
            <div class="w-8 h-8 rounded bg-slate-100 dark:bg-zinc-800 border border-slate-200 dark:border-zinc-700 flex items-center justify-center">
              <svg class="w-4 h-4 text-sky-600 dark:text-sky-400" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path></svg>
            </div>
            <span class="text-slate-700 dark:text-zinc-300 font-medium">Creatine Research</span>
          </div>
          <p class="text-sm text-slate-600 dark:text-zinc-500 mb-6 max-w-xs">Evidence-based creatine research. Every claim cited. No marketing hype.</p>
          <a href="#newsletter" class="inline-block px-5 py-2 text-sm font-semibold bg-sky-600 hover:bg-sky-500 text-white rounded-md transition-colors">Research Updates</a>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Research</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/science" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Science</a></li>
            <li><a href="/dosing" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Dosing</a></li>
            <li><a href="/safety" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Safety</a></li>
          </ul>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Applications</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/sports" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">By Sport</a></li>
            <li><a href="/comparisons" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Comparisons</a></li>
            <li><a href="/quality" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Product Quality</a></li>
          </ul>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Guides</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/science/creatine-mechanisms-summary" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Science Guide</a></li>
            <li><a href="/dosing/creatine-dosing-protocols-summary" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Dosing Guide</a></li>
            <li><a href="/safety/creatine-safety-complete-guide" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Safety Guide</a></li>
            <li><a href="/quality/creatine-buying-guide" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Buying Guide</a></li>
          </ul>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Site</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Home</a></li>
            <li><a href="/articles" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">All Articles</a></li>
            <li><a href="https://scalewithsearch.com" target="_blank" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Scale With Search</a></li>
          </ul>
        </div>
      </div>
      <div class="pt-8 border-t border-slate-200 dark:border-zinc-900 flex flex-col md:flex-row items-center justify-between gap-4">
        <p class="text-xs text-slate-500 dark:text-zinc-700">&copy; 2026 Creatine Research. All cited sources are property of their respective authors.</p>
        <p class="text-xs text-slate-500 dark:text-zinc-700">Powered by <a href="https://scalewithsearch.com" target="_blank" class="text-slate-600 dark:text-zinc-500 hover:text-sky-500">Scale With Search</a></p>
      </div>
    </div>
  </footer>


  <script>
    // Theme
    if (localStorage.theme === 'light') {
      document.documentElement.classList.remove('dark');
    } else if (localStorage.theme === 'dark' || !('theme' in localStorage)) {
      document.documentElement.classList.add('dark');
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
      document.documentElement.classList.add('dark');
    }

    // Mega menu
    (function() {
      const triggers = document.querySelectorAll('.mega-trigger');
      const panels = document.querySelectorAll('.mega-panel');
      let activePanel = null;
      let closeTimeout = null;

      function openPanel(id) {
        clearTimeout(closeTimeout);
        panels.forEach(p => { p.classList.add('hidden'); });
        triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
        const panel = document.getElementById('mega-' + id);
        const trigger = document.querySelector('[data-mega="' + id + '"] .mega-trigger');
        if (panel) { panel.classList.remove('hidden'); activePanel = panel; }
        if (trigger) trigger.setAttribute('aria-expanded', 'true');
      }

      function scheduleClose() {
        closeTimeout = setTimeout(() => {
          panels.forEach(p => p.classList.add('hidden'));
          triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
          activePanel = null;
        }, 200);
      }

      function cancelClose() { clearTimeout(closeTimeout); }

      triggers.forEach(btn => {
        const wrapper = btn.closest('[data-mega]');
        const id = wrapper.getAttribute('data-mega');
        btn.addEventListener('mouseenter', () => openPanel(id));
        btn.addEventListener('click', (e) => {
          e.preventDefault();
          const panel = document.getElementById('mega-' + id);
          if (panel && !panel.classList.contains('hidden')) {
            panel.classList.add('hidden');
            btn.setAttribute('aria-expanded', 'false');
          } else {
            openPanel(id);
          }
        });
        wrapper.addEventListener('mouseleave', scheduleClose);
      });

      panels.forEach(panel => {
        panel.addEventListener('mouseenter', cancelClose);
        panel.addEventListener('mouseleave', scheduleClose);
      });

      document.addEventListener('click', (e) => {
        if (!e.target.closest('[data-mega]') && !e.target.closest('.mega-panel')) {
          panels.forEach(p => p.classList.add('hidden'));
          triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
        }
      });

      document.addEventListener('keydown', (e) => {
        if (e.key === 'Escape') {
          panels.forEach(p => p.classList.add('hidden'));
          triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
        }
      });
    })();

    // Mobile menu
    const mobileMenuBtn = document.getElementById('mobile-menu-btn');
    const mobileMenu = document.getElementById('mobile-menu');
    const menuIcon = document.getElementById('menu-icon');
    const closeIcon = document.getElementById('close-icon');
    if (mobileMenuBtn) {
      mobileMenuBtn.addEventListener('click', () => {
        mobileMenu.classList.toggle('hidden');
        menuIcon.classList.toggle('hidden');
        closeIcon.classList.toggle('hidden');
      });
    }

    // Mobile accordion sections
    document.querySelectorAll('.mobile-section-toggle').forEach(btn => {
      btn.addEventListener('click', () => {
        const section = btn.nextElementSibling;
        const chevron = btn.querySelector('svg');
        section.classList.toggle('hidden');
        chevron.style.transform = section.classList.contains('hidden') ? '' : 'rotate(180deg)';
      });
    });
  </script>
</body>
</html>